四川百利天恒：聚焦肿瘤大分子治疗领域的综合性生物医药企业通过港交所聆讯，或很快香港上市

Group 1 - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is preparing for an IPO in Hong Kong with Goldman Sachs, JPMorgan, and CITIC Securities as joint sponsors [1] - The funds raised from the IPO will be allocated for R&D of candidate biopharmaceuticals outside mainland China, establishing a global supply chain, and operational funding for overseas business [1][2] - The company focuses on innovative biopharmaceuticals and has a leading position in the field of tumor macromolecule therapy, with a core product, iza-bren, being the first of its kind to enter Phase III clinical trials [2] Group 2 - Sichuan Baili Tianheng operates two main business segments: innovative biopharmaceuticals and generic/traditional Chinese medicine, with the former supported by the latter [2] - The company has established dual R&D centers in Seattle, USA, and China, employing a team of 1,360 researchers [2] - As of the latest feasible date, the company has 15 clinical-stage candidate drugs in its innovative pipeline, with iza-bren having submitted a new drug application for nasopharyngeal carcinoma in China [2]